You are here:

paliperidone prolonged-release tablets (INVEGA)


Following a full submission

paliperidone (Invega®) is not recommended for use within NHS Scotland for the treatment of schizophrenia.

Paliperidone has been shown to be superior to placebo in reducing symptoms of schizophrenia. However, there are limited statistical comparative data versus other atypical antipsychotics.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: paliperidone prolonged-release tablets (INVEGA)
SMC Drug ID: 453/08
Manufacturer: Janssen-Cilag Ltd
Indication: Treatment of schizophrenia
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 7 April 2008